1.30
+0.03(+2.36%)
Currency In USD
| Previous Close | 1.27 |
| Open | 1.25 |
| Day High | 1.32 |
| Day Low | 1.25 |
| 52-Week High | 2.32 |
| 52-Week Low | 0.92 |
| Volume | 1.45M |
| Average Volume | 1.33M |
| Market Cap | 496.59M |
| PE | -3.61 |
| EPS | -0.36 |
| Moving Average 50 Days | 1.32 |
| Moving Average 200 Days | 1.32 |
| Change | 0.03 |
If you invested $1000 in Standard BioTools Inc. (LAB) 10 years ago, it would be worth $160.89 as of October 01, 2025 at a share price of $1.3. Whereas If you bought $1000 worth of Standard BioTools Inc. (LAB) shares 5 years ago, it would be worth $164.35 as of October 01, 2025 at a share price of $1.3.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Standard BioTools and Precision Health Research, Singapore (PRECISE-SG100K) Launch Proteomics Collaboration, Selecting SomaScan to Power Large-Scale Population Health Study
GlobeNewswire Inc.
Aug 06, 2025 11:00 AM GMT
PRECISE-SG100K will run 100,000 samples as part of an effort to transform precision health and medicine Reinforces SomaScan’s strategic position in the high-impact biobank segment and its increasing role in leading global health initiatives SOUTH SAN
Standard BioTools Schedules Second Quarter Earnings Conference Call on August 11, 2025
GlobeNewswire Inc.
Jul 21, 2025 11:00 AM GMT
SOUTH SAN FRANCISCO, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report second quarter 2025 financial results on Monday, August 11, 2025, after market close. The company will host a co
Standard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to Illumina
GlobeNewswire Inc.
Jun 23, 2025 11:05 AM GMT
Up To $425 Million In Total Proceeds Inclusive of Near-term Milestone Payments; $350 Million In Upfront Cash Retains Strategic Upside with Illumina Protein Prep Royalty Stream and Rights to Single SOMAmer Reagent Business Simplifies Operating Str
Data not available